A small-to-medium sized Biopharma company with a recently launched product in the Oncology space wanted to expand their eligible patient population by driving the adoption of appropriate biomarker testing – i.e., having more patients tested at the right time with the right type of test and via the right testing channels.
Would you like to learn more about our approach to influence HCP testing behavior and drive product usage?
